American Express, Eli Lilly, Live Nation: CNBC Final Trade - American Express (NYSE: AXP), Eli Lilly
American Express reported upbeat Q1 2026 results on April 23, with net-of-interest-expense revenue up 10% year over year to $18.91B, above the $18.62B consensus, driven by higher card spending, net interest income, card balances and fee growth. CNBC also highlighted Eli Lilly’s FDA approval of EBGLYSS for atopic dermatitis and Live Nation’s move toward a 52-week high; Morgan Stanley raised its LYV price target to $200 from $185.
How this was made
The 30-second read
Why it matters
AXP: earnings beat on card spending and net interest income. LLY: FDA approval for EBGLYSS maintenance dosing in atopic dermatitis. LYV: Overweight reiteration with a higher price target amid strong stock performance.
Market read
Traders get three discrete catalysts: an earnings beat (AXP), a regulatory approval (LLY), and an analyst PT increase (LYV), each aligned with the day’s positive price action.
What to watch
For LLY, competitive landscape, pricing/reimbursement, and uptake speed are not discussed; for LYV, the PT raise may be sentiment/valuation-driven without new operational data.
Background
This is a multi-name “final trade” style wrap combining AXP’s Q1 results, LLY’s FDA approval, and LYV’s analyst/PT update alongside reported price moves.
Ticker impact
American Express reported Q1 2026 revenue (net of interest expense) up 10% YoY to $18.91B, beating consensus $18.62B.
Supportive bias for AXP versus peers; follow-through depends on guidance not provided here.
The article provides concrete beat figures and key drivers, but no forward guidance or margin detail to gauge magnitude beyond the beat.
FDA approved Eli Lilly’s EBGLYSS (lebrikizumab-lbkz) for one maintenance dose every eight weeks in atopic dermatitis.
Likely positive momentum for LLY as traders price in incremental sales and reduced regulatory risk.
The text states a specific FDA approval with dosing schedule and indication, which is a primary catalyst.
Live Nation shares were described as near a new 52-week high, with Morgan Stanley raising its price target to $200 from $185.
Near-term bullish bias, though magnitude depends on whether the PT change reflects new fundamentals not detailed here.
The article includes a specific PT increase and Overweight rating, but provides no new company-specific operational catalyst beyond the analyst action.
Market effects
Financials: AXP’s card spending strength reinforces consumer/credit-card demand read-through. Pharma: LLY’s FDA approval supports broader dermatology/biologics sentiment. Media/entertainment: LYV’s analyst PT raise can lift sentiment toward live events demand.
Primarily US-focused catalysts (FDA approval; US earnings/analyst actions).
Limited global spillover beyond pharma regulatory sentiment and US consumer spending signals.
Counterpoint
The article lacks forward guidance for AXP and does not quantify EBGLYSS commercial expectations for LLY, so the market may already be pricing parts of these catalysts.
Key entities
- companyAmerican Express
Reported Q1 2026 results with revenue growth and a consensus beat.
- companyEli Lilly
Received FDA approval for EBGLYSS in atopic dermatitis with an eight-week maintenance dosing schedule.
- companyLive Nation Entertainment
Morgan Stanley maintained Overweight and raised its price target to $200.
